Literature DB >> 27550546

Low Levels of MicroRNA-21 Are a Marker of Reduced Arterial Stiffness in Well-Controlled Hypertension.

Fragiskos Parthenakis1, Maria Marketou1, Joanna Kontaraki2, Alexandros Patrianakos1, Helen Nakou1, Maria Touloupaki1, Michail Vernardos1, George Kochiadakis1, Gregory Chlouverakis3, Panos Vardas1.   

Abstract

MicroRNAs (miRNAs) play a crucial role in myocardial and vascular remodeling and have emerged as potential diagnostic and prognostic biomarkers or as therapeutic targets. The authors aimed to investigate the expression profile of selected miRNAs in the peripheral blood of patients with well-controlled essential hypertension in relation to arterial stiffness. Expression levels of miRNAs miRNA-1, miRNA-133a, miRNA-26b, miRNA-208b, miRNA-499, and miRNA-21 in peripheral blood mononuclear cells were quantified by real-time reverse transcription polymerase chain reaction. Carotid-femoral pulse wave velocity (cfPWV) and carotid radial pulse wave velocity (crPWV) were evaluated at baseline and after 1 year of effective antihypertensive therapy. A total of 95 patients (50 men, mean age 62±9 years) with well-controlled essential hypertension were included in the analysis. Only miRNA-21 was independently correlated with changes in both cfPWV and crPWV, independently of blood pressure levels (r=-0.56 and r=-0.46, respectively; P<.001 for both). Low levels of miRNA-21 are strongly associated with an improvement in arterial stiffness in patients with well-controlled essential hypertension, independently of their blood pressure levels. These data highlight the significance of miRNA-21 in vascular remodeling and its role as a potential prognostic marker and future therapeutic target. ©2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27550546      PMCID: PMC8031006          DOI: 10.1111/jch.12900

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  31 in total

Review 1.  Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis.

Authors:  Charalambos Vlachopoulos; Konstantinos Aznaouridis; Christodoulos Stefanadis
Journal:  J Am Coll Cardiol       Date:  2010-03-30       Impact factor: 24.094

Review 2.  Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review.

Authors:  Marina Cecelja; Philip Chowienczyk
Journal:  Hypertension       Date:  2009-11-02       Impact factor: 10.190

Review 3.  MicroRNAs as biomarkers of disease onset.

Authors:  Maciej Ciesla; Klaudia Skrzypek; Magdalena Kozakowska; Agnieszka Loboda; Alicja Jozkowicz; Jozef Dulak
Journal:  Anal Bioanal Chem       Date:  2011-05-06       Impact factor: 4.142

4.  MiR-21 suppresses endothelial progenitor cell proliferation by activating the TGFβ signaling pathway via downregulation of WWP1.

Authors:  Keqiang Zuo; Maoquan Li; Xiaoping Zhang; Chenghui Lu; Shi Wang; Kangkang Zhi; Bin He
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

Review 5.  Resistance and conduit arteries following converting enzyme inhibition in hypertension.

Authors:  M E Safar; L M van Bortel; H A Struijker-Boudier
Journal:  J Vasc Res       Date:  1997 Mar-Apr       Impact factor: 1.934

6.  Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension.

Authors:  Joanna E Kontaraki; Maria E Marketou; Fragiskos I Parthenakis; Spyros Maragkoudakis; Evangelos A Zacharis; Stelios Petousis; George E Kochiadakis; Panos E Vardas
Journal:  J Am Soc Hypertens       Date:  2015-08-01

7.  Local overexpression of monocyte chemoattractant protein-1 at vessel wall induces infiltration of macrophages and formation of atherosclerotic lesion: synergism with hypercholesterolemia.

Authors:  Masayuki Namiki; Seinosuke Kawashima; Tomoya Yamashita; Masanori Ozaki; Tetsuaki Hirase; Tatsuro Ishida; Nobutaka Inoue; Ken-ichi Hirata; Akihiro Matsukawa; Ryuichi Morishita; Yasufumi Kaneda; Mitsuhiro Yokoyama
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-01       Impact factor: 8.311

8.  Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by induction of microRNA-21.

Authors:  Cristina I Caescu; Xingyi Guo; Lydia Tesfa; Tushar D Bhagat; Amit Verma; Deyou Zheng; E Richard Stanley
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113

Review 9.  MicroRNAs in myocardial infarction.

Authors:  Jan Fiedler; Thomas Thum
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02       Impact factor: 8.311

10.  MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4.

Authors:  Yunhui Cheng; Xiaojun Liu; Shuo Zhang; Ying Lin; Jian Yang; Chunxiang Zhang
Journal:  J Mol Cell Cardiol       Date:  2009-01-27       Impact factor: 5.000

View more
  13 in total

Review 1.  The Epigenetic Machinery in Vascular Dysfunction and Hypertension.

Authors:  Emile Levy; Schohraya Spahis; Jean-Luc Bigras; Edgard Delvin; Jean-Michel Borys
Journal:  Curr Hypertens Rep       Date:  2017-06       Impact factor: 5.369

2.  Extracellular vesicles as a novel diagnostic and research tool for patients with HTN and kidney disease.

Authors:  Uta Erdbrügger; Thu H Le
Journal:  Am J Physiol Renal Physiol       Date:  2019-07-17

Review 3.  Insights Into Platelet-Derived MicroRNAs in Cardiovascular and Oncologic Diseases: Potential Predictor and Therapeutic Target.

Authors:  Qianru Leng; Jie Ding; Meiyan Dai; Lei Liu; Qing Fang; Dao Wen Wang; Lujin Wu; Yan Wang
Journal:  Front Cardiovasc Med       Date:  2022-06-09

Review 4.  Recent research progress of microRNAs in hypertension pathogenesis, with a focus on the roles of miRNAs in pulmonary arterial hypertension.

Authors:  Chenggui Miao; Jun Chang; Guoxue Zhang
Journal:  Mol Biol Rep       Date:  2018-10-08       Impact factor: 2.316

5.  Deletion of the microRNA-degrading nuclease, translin/trax, prevents pathogenic vascular stiffness.

Authors:  Eric Tuday; Yohei Nomura; Deepa Ruhela; Mitsunori Nakano; Xiuping Fu; Aparna Shah; Barbara Roman; Atsushi Yamaguchi; Steven S An; Charles Steenbergen; Jay M Baraban; Dan E Berkowitz; Samarjit Das
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-10-18       Impact factor: 4.733

Review 6.  Inflammatory Markers for Arterial Stiffness in Cardiovascular Diseases.

Authors:  Ioana Mozos; Clemens Malainer; Jarosław Horbańczuk; Cristina Gug; Dana Stoian; Constantin Tudor Luca; Atanas G Atanasov
Journal:  Front Immunol       Date:  2017-08-31       Impact factor: 7.561

Review 7.  The Role of MicroRNAs in Arterial Stiffness and Arterial Calcification. An Update and Review of the Literature.

Authors:  Sideris Nanoudis; Maria Pikilidou; Maria Yavropoulou; Pantelis Zebekakis
Journal:  Front Genet       Date:  2017-12-12       Impact factor: 4.599

Review 8.  Non-Coding RNA in the Pathogenesis, Progression and Treatment of Hypertension.

Authors:  Christiana Leimena; Hongyu Qiu
Journal:  Int J Mol Sci       Date:  2018-03-21       Impact factor: 5.923

9.  Low Levels of MicroRNA-21 Are a Marker of Reduced Arterial Stiffness in Well-Controlled Hypertension.

Authors:  Fragiskos Parthenakis; Maria Marketou; Joanna Kontaraki; Alexandros Patrianakos; Helen Nakou; Maria Touloupaki; Michail Vernardos; George Kochiadakis; Gregory Chlouverakis; Panos Vardas
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-08-22       Impact factor: 3.738

10.  Degradation of Premature-miR-181b by the Translin/Trax RNase Increases Vascular Smooth Muscle Cell Stiffness.

Authors:  Eric Tuday; Mitsunori Nakano; Kei Akiyoshi; Xiuping Fu; Aparna P Shah; Atsushi Yamaguchi; Charles Steenbergen; Lakshmi Santhanam; Steven S An; Dan Berkowitz; Jay M Baraban; Samarjit Das
Journal:  Hypertension       Date:  2021-07-26       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.